Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Hutchmed
Stanford University
Stanford University
BeiGene
TopAlliance Biosciences
Rain Oncology Inc
Stanford University
Ipsen
pharmaand GmbH
Novartis
INSYS Therapeutics Inc